The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer

By Keen J.C.  

Breast Cancer Research and Treatment, Vol. 44, Iss. 2, 1997-06 ,pp. : 123-133

Springer Publishing Company

Access to resources Recommend Favorite

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer

By Gökmen-Polar Yesim   Toroni Rachel   Hocevar Barbara   Badve Sunil   Zhao Qianqian   Shen Changyu   Bruckheimer Elizabeth   Kinch Michael   Miller Kathy  

Breast Cancer Research and Treatment, Vol. 127, Iss. 2, 2011-06 ,pp. : 375-384

Springer Publishing Company

Access to resources Recommend Favorite

Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer

By Reijm E.  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 387-394

Springer Publishing Company

Access to resources Recommend Favorite

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer

By Henriksen Katrine   Rasmussen Birgitte   Lykkesfeldt Anne   Møller Susanne   Ejlertsen Bent   Mouridsen Henning  

Acta Oncologica, Vol. 48, Iss. 4, 2009-05 ,pp. : 522-531

Informa Healthcare

Access to resources Recommend Favorite

Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer

By Buzdar A.  

Breast Cancer Research and Treatment, Vol. 73, Iss. 2, 2002-05 ,pp. : 161-175

Springer Publishing Company

Access to resources Recommend Favorite